Received grant in 2025
DCCC has funded 200,000 DKK to this initiative.
Developing radioactive pharmaceuticals for the treatment of prostate cancer has been a focus for many years. The treatment approach, called radioligand therapy, is a highly relevant area of international research, and many new radioligand therapies are currently under development. In Denmark, a variant of this treatment (Lu-PSMA-I&T) has been used for several years, showing promising results for survival, but the treatment is not yet available nationwide. Therefore, there is a need for solid documentation on the dose and treatment regimen that provides the best balance between efficacy and side effects.
The applicants behind this initiative plan a national, randomized trial involving 420 men with metastatic prostate cancer to investigate whether dose-escalated Lu-PSMA-I&T can improve treatment efficacy without increasing the risk of side effects compared to the standard dosing. The study, which is the first Danish investigator-initiated phase III trial on medical cancer treatment for men with prostate cancer, could provide Danish patients access to an important targeted therapy that is currently only available in very limited capacity.
Before the study can be initiated, a full protocol must be developed, additional funding must be secured, and a national study leadership team must be established. The grant from DCCC will support protocol writing, preparation of grant applications, and meeting activities within the research group.
The study is expected to increase national knowledge of radioligand therapy, strengthen collaboration across centres, and provide important insights into the production, handling, and safe use of radioactive pharmaceuticals in cancer treatment.
Multidisciplinary organisation
The initiative is supported by the Danish Prostate Cancer Group (DAPROCA) and the Danish Society of Clinical Physiology and Nuclear Medicine (DSKFNM).
Project stakeholders
Aarhus University Hospital
- Peter Iversen, Consultant, PhD, Department of Nuclear Medicine. Primary contact, mail: peiver@rm.dk
- Dirk Andreas Bender, PhD, Associate Professor, Chief Chemist, QP
- Peter Frøhlich Staanum, Medical Physicist, PhD
- Mads Ryø Jochumsen, MD, PhD
- Simon Buus, Consultant, PhD, Department of Oncology. Member of DAPROCA
- Michael Borre, Consultant, Professor, DMSc, PhD, Department of Urology. Chair of DAPROCA
- Karina Dalsgaard Sørensen, Professor, PhD, Department of Molecular Medicine (MOMA). Member of DAPROCA
- Maria Rusan, Consultant, PhD, Department of Molecular Medicine (MOMA) and Department of Clinical Pharmacology
Aalborg University Hospital
- Jimmi Søndergaard, Consultant, PhD, Department of Oncology. Member of DAPROCA.
- Helle D Zacho, Professor, Consultant, PhD, DMSc, Department of Nuclear Medicine. Member of DAPROCA.
Herlev & Gentofte Hospital
- Claus Madsen, Consultant, Department of Clinical Physiology and Nuclear Medicine
- Dan Fuglø, Consultant, PhD, Department of Clinical Physiology and Nuclear Medicine
- Lisbeth Marner, DMSc, PhD, Consultant, Department of Clinical Physiology and Nuclear Medicine
- Anders Frellsen, Radiochemist, Head of Production, PhD
- Henriette Lindberg, Consultant, PhD, Department of Oncology. Member of DAPROCA
- Per Kongsted, MD, PhD, Department of Oncology
- Peter Busch Østergren, Consultant, PhD, Department of Urology. Deputy Chair of DAPROCA
Vejle Hospital
- Paw Christian Holdgaard, Head of Department, Department of Nuclear Medicine. Member of Danish Anal Cancer Group.
- Christine Vestergård Madsen, Head of Department, PhD, Department of Oncology. Member of DAPROCA
Odense University Hospital
- Karen Middelbo Buch-Olsen, Nuclear Medicine Specialist, Department of Nuclear Medicine
- Christian Glarbo T Pedersen, Medical Physicist, Department of Nuclear Medicine
- Steinbjørn Hansen, Consultant, Clinical Associate Professor, PhD, Department of Oncology
Rigshospitalet
- Camilla Bardram Johnbeck, MD, PhD, Lead of Radionuclide Therapy, Department of Clinical Physiology, Nuclear Medicine and PET
- Jann Mortensen, Professor, Consultant, DMSc, Department of Clinical Physiology and Nuclear Medicine
- Peter Meidahl Petersen, Consultant, PhD, Department of Oncology. Member of DAPROCA